Category:

Investors

Greenlight Biosciences Appoints Diane Griffin and Emmanuel Hanon to its Human Health Scientific Advisory Board

GreenLight Biosciences is delighted to announce the appointment of Professor Diane E. Griffin, MD, PhD, and Emmanuel Hanon, DVM, PhD, to its Human Health Scientific Advisory Board.

At Johns Hopkins University, Diane Griffin is the Distinguished Service Professor, a professor of Medicine and Neurology at the School of Medicine, and the W. Harry Feinstone professor at the Department of Molecular Microbiology and Immunology at the Bloomberg School of Public Health. She has also been vice president of the U.S. National Academy of Sciences since 2013. Professor Griffin brings the experience of a distinguished career to facilitate the R&D work of GreenLight, especially her focus on pathogenesis of acute RNA virus infections and the role of the immune response in virus clearance, protection from infection, and mechanisms of vaccine-induced protection.

Emmanuel Hanon’s 20-year career at GlaxoSmithKline included 7 years as the GSK Vaccines’ senior vice president and head of R&D. As a virologist and immunologist, he made critical contributions to next-generation adjuvants and their inclusion in successful vaccines for pandemic influenza, malaria, and shingles. He currently serves as head of R&D for Viome, a precision medicine company focusing on chronic disorders. Dr. Hanon’s experience in vaccinology and product development will be critical in helping GreenLight accelerate its development programs.

Amin Khan, GreenLight’s Human Health chief scientific officer, said: “GreenLight aims to solve some of the world’s biggest problems by delivering on the full potential of RNA, including producing vaccines and gene therapies. We’re delighted that Diane and Emmanuel have joined our Scientific Advisory Board. Their expertise in virology, immunology, public health, and product development will help us accelerate our progress.”

About GreenLight Biosciences, Inc.
Founded in 2008, GreenLight’s aims to solve some of the world’s biggest problems by delivering on the full potential of RNA for human health and agriculture.

In human health, this includes mRNA vaccines and therapeutics. In agriculture, this includes RNA to protect honeybees and a range of crops. The company’s breakthrough cell-free RNA manufacturing platform, which is protected by numerous patents, allows for cost-effective and scalable production of RNA. For more information, visit https://www.greenlightbiosciences.com/

By 0 Comments

a fruit covered in mould with a WIRED graphic in front

Wired: The Next Big Thing for RNA

Credit: Wired/PAUL STAROSTA/GETTY IMAGES

Mark Singleton, Head of Plant and Animal Health at GreenLight Biosciences, speaks to Wired magazine about the potential of RNA to fix moldy food by defending against Botrytis and other pests. Extracts from the article are below:

“It’s the big one,” says Mark Singleton, head of plant and animal health at GreenLight Biosciences, a Massachusetts-based biotech startup working on a new generation of sprays to defend against Botrytis and other pests that bedevil farmers…

GreenLight Biosciences has an RNA spray targeting the Colorado potato beetle that’s currently being evaluated by the Environmental Protection Agency. The company is expecting a decision on that spray by the middle of 2022. It’s also working on a spray for Botrytis, as well as one that combats the Varroa mite, a widespread pest that infects honey bees. After initial laboratory trials, GreenLight is now field testing its Botrytis spray on grapes in California and strawberries in Italy. Singleton says they’re looking to find out how long the spray sticks to plants and how it compares to chemical fungicides.

Read the full article here.

Find out more about how GreenLight manufactures RNA here.

By 0 Comments

GreenLight Biosciences (ENVI) Science Day updates investors on progress across human, plant and animal health

7 agricultural products in development with an addressable market of $6bn that we plan to launch by 2026.

Control of fungal pathogens using double-stranded RNA has been demonstrated in field testing for the first time. This addresses the number one cause of food rotting.

Varroa mite: Higher brood and health scores compared to chemical controls.

Promising antibody response and cell-mediated immunity for GreenLight Covid-19 vaccine candidates in mice. Data indicates feasibility of initiating clinical trial in Africa for COVID-19 vaccine candidate.

Gene therapy: Bill & Melinda Gates Foundation milestone achieved. Moving to next phase of research.

BOSTON, MASS: Today GreenLight Biosciences (ENVI) will hold Science Day to update investors on the company’s progress towards solving some of the world’s largest and most difficult problems by delivering on the full potential of RNA.

“Today we will show important results for the use of RNA across our pipeline of human, plant and animal health applications,” said Andrey Zarur, GreenLight co-founder and CEO. “Core to these developments is our success in developing our platform for design, development and production of unprecedented new applications for RNA.”

Human health results

Covid-19 vaccine: Promising antibody response and cell-mediated immunity for GreenLight Covid-19 vaccine candidates in mice. GreenLight candidates induced humoral responses exceeding WHO standard. GreenLight candidates induced Th1-biased cell mediated immune responses. Promising disease protection results for GreenLight Covid-19 vaccine candidates in hamsters. All tested doses protected against morbidity. GreenLight plans to start Phase I clinical trial in Africa in Q1 2022.

Gene therapy: Tools have been created by GreenLight RNA-encoded instructions, with evidence of transgene expression. Bill & Melinda Gates Foundation milestone achieved allowing for next phase of grant work.


Plant and animal health progress

Grape Powdery Mildew: Lab results translates to field level control consistent with commercial standards.

Botrytis: GreenLight sequences, without enhancement from formulation, demonstrate Botrytis control in strawberries field trials. Trials at two sites show reduction in disease severity compared to untreated check. Application of naked dsRNA to whole tomato plants in greenhouse cuts disease severity. Sequence, without enhancement from formulation, reduces severity by 46-59% compared to untreated control.

Fusarium: First sequences show promise with direct application to fusarium. 25% to 40% reduction of in vitro fusarium, relative to untreated control. Application to infected wheat seedlings shows 25% to 50% reduction of vomitoxin (DON) and fusarium, relative to untreated control.

Pollen beetle: First sequences drive statistically significant pollen beetle mortality. Lab study shows 20% to 80% pollen beetle mortality in vitro. Sequences show promise with application on oilseed rape plants, with 40% pollen beetle mortality in vivo relative to untreated control.

Two spotted spider mite: First sequences drive statistically significant mortality rates of two spotted spider mite. Lab study shows adult females survival near zero in vitro within ten days of application to leaf disc.

Diamondback moth & other lepidoptera. To date, ingested dsRNA has not been viable for control of Diamondback moth and Fall armyworm. A delivery technology under evaluation increases the impact of dsRNA sequences. Our approach enables a 50% increase in diamondback moth mortality and 90% lower weight in fall armyworm larvae, compared to naked dsRNA.

Bee health: Key part of acquired IP portfolio translated into positive field trial results in less than 8 months. 40% fewer Varroa destructor mites at 12 weeks in hives with GreenLight fields tests compared with the leading chemical control product. Strong efficacy compared to a leading chemical control. Treatments improved bee brood and hive health compared to chemical controls.

For full results and context please refer to the Science Day for investors presentation on our Investors page.

Notes to editors

Markets addressed by today’s updates:

Area+Indicative addressable market

Fusarium: $950m

Pollen beetle $185m

Two-spotted spider mite $1,100m

Diamondback moth $890m

Powdery mildew $1,400m

Varroa mite $290m

About GreenLight

Founded in 2008, GreenLight aims to solve some of the world’s biggest problems by delivering on the full potential of RNA for human health and agriculture.

In human health, this includes mRNA vaccines and therapeutics. In agriculture, this includes RNA to protect honeybees and a range of crops. The company’s breakthrough cell-free RNA manufacturing platform, which is protected by numerous patents, allows for cost-effective and scalable production of RNA. For more information, visit https://www.greenlightbiosciences.com/


In August 2021, GreenLight Biosciences announced plans to become publicly listed through a business combination with Environmental Impact Acquisition Corp. (Nasdaq:ENVI).

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws with respect to the business of GreenLight Biosciences, Inc. and its proposed transaction with Environmental Impact Acquisition Corp. (“ENVI”), including statements regarding the anticipated benefits and uses of GreenLight’s product candidates, the market opportunities for GreenLight’s product candidates, timing of clinical trials, and the timing of commercial launch of product candidates, and the anticipated business combination with ENVI. These forward-looking statements are generally identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from these forward-looking statements, including but not limited to: the need to obtain regulatory approval for GreenLight’s product candidates; the risk that clinical trials will not demonstrate that GreenLight’s therapeutic product candidates are safe and effective; the risk that GreenLight’s product candidates will have adverse side effects or other unintended consequences, which could impair their marketability; the risk that GreenLight’s product candidates do not satisfy other legal and regulatory requirements for marketability in one or more jurisdictions; the risks of enhanced regulatory scrutiny of mRNA solutions; the risk of significant delays in research, development, testing, clinical trials and regulatory approval; the potential inability to achieve GreenLight’s goals regarding scalability and affordability of its product candidates; the anticipated need for additional capital to achieve GreenLight’s business goals; changes in the industries in which GreenLight operates; changes in laws and regulations affecting the business of GreenLight; the risk that the proposed business combination with ENVI may not be completed in a timely manner or at all, which may adversely affect the price of ENVI’s securities; the failure to satisfy conditions to the consummation of the transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the business combination agreement; risks that the proposed transaction disrupts current plans and operations of GreenLight; and the potential inability to implement or achieve business plans, forecasts, and other expectations after the completion of the proposed transaction. The foregoing list of factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the registration statement on Form S-4 discussed below and other documents filed by ENVI from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and ENVI and GreenLight assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Neither ENVI nor GreenLight gives any assurance that GreenLight or ENVI, or the combined company, will achieve any result described in any forward-looking statement.

Important Information and Where to Find It

This press release may be deemed to relate to a proposed transaction between GreenLight Biosciences, Inc. and Environmental Impact Acquisition Corp. This press release does not constitute either (a) a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed business combination or (b) an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.


ENVI has filed a registration statement on Form S-4 with the SEC, which includes a document that serves as a preliminary prospectus and proxy statement of ENVI, referred to as a proxy statement/prospectus. The final proxy statement/prospectus will be sent to all ENVI shareholders after the registration statement is declared effective by the SEC. ENVI also will file other documents regarding the proposed transaction with the SEC. This press release does not contain all of the information that will be contained in the final proxy statement/prospectus or other documents filed with the SEC. Before making any voting decision, investors and security holders of ENVI are urged to read the registration statement, the final proxy statement/ prospectus and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction.

Investors and security holders will be able to obtain free copies of the registration statement, the final proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by ENVI through the website maintained by the SEC at www.sec.gov or by sending a written request to ENVI at: [email protected]

Participants in the Solicitation

ENVI, GreenLight and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from ENVI’s shareholders in connection with the proposed transaction. A list of the names of such directors and executive officers and information regarding their interests in the proposed business combination will be contained in the final proxy statement/prospectus when available. You may obtain free copies of these documents as described in the preceding paragraph.

Contact:

Thomas Crampton

SVP & Head of Corporate Affairs

GreenLight Biosciences

[email protected]

+1 914 202 2762

+44 7826 995794

By 0 Comments

A GreenLight scientist pipettes liquid on a bench

The Washington Post: GreenLight plans to launch a clinical trial in Africa next year

The Washington Post reports on GreenLight Biosciences’ plans to launch a clinical trial in Africa next year.

The Washington Post reports on vaccines in Africa and mentions GreenLight Bioscience’s plans to launch a clinical trial in Africa next year. An extract is below:

GreenLight Biosciences, a start-up company that has been making RNA for agricultural applications, is working toward making mRNA vaccines with a different manufacturing process that could be easier to scale up. GreenLight plans to launch a clinical trial in Africa next year.

Read the full article here.

Find out more about how GreenLight manufactures RNA here.

By 0 Comments

a scientist in a clean suit works on a GreenLight bench

Business Insider: COVID-19 vaccines sparks expansion of RNA research

Business Insider reports on GreenLight Bioscience’s plans to expand its RNA research work, including to include human therapeutics. An extract from the article is below:

For instance, GreenLight Biosciences expanded its mRNA work last year from focusing on pesticide alternatives to include human therapeutics. Now, GreenLight is riding the mRNA hype to a public debut, agreeing to a $1.2 billion special-purpose acquisition company deal in August.

“GreenLight aims to solve some of the world’s biggest problems with RNA, from affordable vaccines and therapies to protecting honeybees,” GreenLight CEO Andrey Zarur said in a statement, adding that clinical trials for its COVID-19 vaccine were scheduled to begin next year.

Read the full article here.

Find out more about how GreenLight manufactures RNA here.

By 0 Comments

VP of marketing Catie Lee is interviewed by news media at Greenlight factory

GreenLight Biosciences opens RNA production facility for the next generation of agricultural products

GreenLight Biosciences, Inc., a biotechnology company focused on RNA research, design, and manufacturing for human, animal, and plant health, today announced the opening of its manufacturing plant in Rochester, New York.

The 17,000-square-foot facility will manufacture enzymes and RNA for a variety of agricultural applications, including the protection of honeybees.

While the fast rollout of mRNA vaccines helped change the course of the pandemic, RNA also has numerous potential applications in plant and animal health.

To date, however, the cost and scale of RNA production has constrained the development of its use in agriculture.

“GreenLight has developed a new way to produce commercial quantities of RNA at low cost for multiple applications,” says chief operating officer Carole Cobb. “GreenLight’s research know-how and production process allows us to address some of the challenges that formerly hindered RNA’s application in agriculture.”

Sustainable alternatives to chemical-based pesticides are needed to protect biodiversity, including beneficial insects and pollinators. GreenLight’s agricultural solutions are designed to protect biodiversity through their specificity in targeting pests like the Varroa destructor mite, which contributes to the collapse of beehives, and the Colorado potato beetle, which destroys potato plants.

“Rochester has a proud history of being on the cutting edge of technological innovation, and GreenLight Biosciences continues that legacy,” said Rep. Joe Morelle (D–N.Y.). “This new production facility will be critical to advancing RNA applications and strengthening our agricultural economy. I am excited to welcome GreenLight Biosciences into Eastman Business Park and look forward to their continued growth and success.”

Located within the 1,200-acre Eastman Business Park, the Rochester manufacturing facility has an installed capacity at 500 kg per year, with ready expansion to 1,000 kg. The site and utility infrastructure supports a further expansion of RNA production up to 100 metric tons per year.

About GreenLight Biosciences, Inc. 

Founded in 2008, GreenLight has raised approximately $235 million to date and is rapidly expanding to new market opportunities in human health, animal health, and plant health. 

GreenLight harnesses the power of biology to develop RNA-based solutions for some of humanity’s greatest challenges in human health through mRNA vaccines and therapeutics and in food production through RNA crop-protection products. The company’s breakthrough cell-free RNA manufacturing platform, which is protected by numerous patents, allows for cost-effective and scalable production of RNA. For more information, visit https://www.greenlightbiosciences.com/

In August 2021, GreenLight Biosciences announced plans to become publicly listed through a business combination with Environmental Impact Acquisition Corp. (Nasdaq:ENVI).

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, with respect to the proposed transaction between GreenLight Biosciences, Inc. (“GreenLight”) and Environmental Impact Acquisition Corp. (“ENVI”). These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of ENVI’s securities and the effect of the announcement or pendency of the transaction on GreenLight’s business relationships, operating results, and business generally. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and ENVI and GreenLight assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact: 

Thomas Crampton

SVP & Head of Corporate Affairs

GreenLight Biosciences

[email protected]

+44 7826 995794

+1-914-202-2762

By 0 Comments

GreenLight acquires Bayer’s topical RNA Intellectual Property portfolio

An RNA product to protect bees against varroa mites

GreenLight Biosciences today announced that they have acquired rights to portions of Bayer’s topical RNA Intellectual Property portfolio. These assets include bee health capabilities to protect against Varroa mites, a major threat to honeybees.

The RNA-based Varroa mite control advance allows beekeepers to directly target the Varroa mite without harming the honeybee, a critical advantage to other treatments on the market today.

RNA’s potential for improving plant, animal and human health has been known for years, but widespread commercial use hasn’t previously been possible, due to RNA’s cost of production, and slow production time.

GreenLight’s proprietary, cell-free method enables the company to produce low-cost, high-quality, high-scale RNA in a safe and environmentally friendly manner.

“GreenLight’s manufacturing capability, along with their technical expertise in RNA applications, made them the ideal candidate to move these technologies forward,” said Shaun Selness, Bayer Head of Emerging Technologies. “Bayer’s project team made significant technical progress over the past several years on an RNA-based Varroa mite control concept and GreenLight is best positioned to bring a cost-effective product to market.”

GreenLight is committed to innovating sustainable solutions for plant health, human health, and animal health, and to making these solutions affordable and accessible.

“GreenLight is working to address humanity’s greatest challenges, from producing vaccines to protecting bees and other beneficial insects like ladybugs. The Covid vaccine has shown just how well scientific advances can be used to protect our health. We can use the same advances to help keep bees healthy – as if we are inoculating whole hives of bees,” said Andrey Zarur, CEO and founder of GreenLight Biosciences. “It is an honor to acquire the rights to Bayer’s groundbreaking technical work, so that we can bring it to beekeepers everywhere.”

You can find out more about GreenLight’s work on bees here.

Update: The Economist has written up GreenLight’s work on bees here.

By 0 Comments